KRAS and juvenile myelomonocytic leukemia: This observation, and more subtle differences between PTPN11 compared with KRAS and NRAS, calls for further investigation in larger cohorts, with also the potential to inform association of circRNA expression with biological and clinical features of patients, useful to establish new biomarkers in JMML.